Phase 1 Trials In a first-in-human, randomized, placebo-controlled, single ascending dose, phase 1 trial in healthy participants, retatrutide demonstrated a favourable safety profile (similar to other incretin-based therapies) and early signs of efficacy with dose-dependent WL [42]
The 3-pattern typology: how patients actually respond to the switch Across clinical experience with patients switching from semaglutide to tirzepatide, three response patterns emerge
He welcomes questions and honestly answers them
It also suggests that retatrutide could eventually find clinical applications beyond weight management
The goal of the study was to ascertain whether GI adverse events (GI AEs), such as nausea/vomiting, diarrhea, constipation, and dyspepsia (indigestion), during the dose escalation phase (baseline to week 12) and from baseline to the end of treatment, are responsible for the greater weight loss seen with semaglutide compared to other GLP-1RAs
CrossRef Nitric oxide pathway: Emerging therapeutic strategies for MASLD Yanling Zhang, Ying Zhang, Hongjin Chen, Fangfang Qi Pathology - Research and Practice .2026